Recent Trading Performance and Business Snapshot

Syndax Pharmaceuticals (SNDX) has drawn fresh attention after recent trading, with the stock closing at US$19.57 on 25 August 2026. The move comes after a month where the share price declined 6%.

Over the past week the stock fell about 2% and is down roughly 8% year to date. By contrast, the past year shows a total return of 23%, with a 3 year total return of 2% and a 5 year total return of 12%.

The company has a market value of about US$1.7b and reported revenue of US$252.3 million with a net loss of US$220.8 million. Reported annual revenue growth was 29% and net income growth was 69%.

Syndax Pharmaceuticals is a commercial stage biopharmaceutical company focused on cancer therapies. Its lead products include Revuforj, a menin inhibitor for relapsed or refractory acute leukemia, and Niktimvo, a colony stimulating factor 1 receptor blocking antibody for chronic graft versus host disease.

The pipeline also includes revumenib programs in acute myeloid leukemia with a nucleophosmin 1 mutation and metastatic colorectal cancer, axatilimab for idiopathic pulmonary fibrosis, and Entinostat, a Class 1 HDAC inhibitor licensed with Eddingpharm International Company Limited.

For investors, Syndax Pharmaceuticals now presents a mixed picture, with recent share price returns over the past month and year to date losing momentum even as the 1 year total shareholder return remains positive, which may hint at shifting expectations around its commercial rollout and pipeline risk.

If you are weighing Syndax Pharmaceuticals against other opportunities in healthcare, it can help to see what else is gaining attention in the sector, including stocks featured in the 40 healthcare AI stocks

Analyst targets and intrinsic value estimates sit well above Syndax Pharmaceuticals' recent US$19.57 close. After this pullback, and with ongoing losses, is the market being overly cautious or simply realistic about the risks ahead?

Most Popular Narrative: 50.5% Undervalued

The most followed narrative on Syndax Pharmaceuticals compares a fair value of $39.50 to the recent $19.57 close. This frames a large valuation gap that hinges on future earnings power and commercial execution.

Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.

Want to see what is built into that $39.50 fair value for Syndax Pharmaceuticals? The narrative leans on rapid revenue expansion, rising margins, and a rich future earnings multiple that many investors usually associate with larger pharma leaders.

Result: Fair Value of $39.50 (UNDERVALUED)

However, Syndax Pharmaceuticals still faces meaningful risk if key trials disappoint or regulators limit label expansions, which could challenge current revenue and earnings assumptions.

Another View On Syndax Pharmaceuticals Valuation

The first narrative leans heavily on future cash flows and analyst targets to call Syndax Pharmaceuticals undervalued. On a simple sales multiple, the picture is more complicated. The stock trades on a P/S of 6.9x compared with a fair ratio of 3.2x and a US Biotechs industry average of 13.3x. That suggests Syndax looks cheaper than peers yet still rich versus what the fair ratio implies. Is the discount to other biotechs enough to offset the risk that the market moves closer to that lower fair ratio?

Next Steps

With sentiment clearly split on Syndax Pharmaceuticals, the most useful step now is to review the detail behind both the optimism and the risks for yourself. Take a closer look at the specific upsides the market is pricing in with the 2 key rewards

Looking For More Investment Ideas Beyond Syndax Pharmaceuticals?

If Syndax Pharmaceuticals has your attention, do not stop there. Broadening your watchlist with other high quality ideas can help you spot opportunities you might otherwise miss.

• Target resilient compounding potential by reviewing companies highlighted in the 74 resilient stocks with low risk scores.
• Hunt for quality at a reasonable price through the 49 high quality undervalued stocks that filters for strong fundamentals and attractive valuations.
• Spot future standouts early by scanning the screener containing 18 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.